Though the United States has made significant progress in the realm of flu vaccines, the country will likely need to wait 5 to 10 years for a universal shot, top federal health officials said.
Carlsbad, CA-based Isis Pharmaceuticals nabbed a $7.5 million milestone payment from GlaxoSmithKline on the launch of a Phase II/III clinical study for ISIS-TTR.
More drugmakers are joining up with anti-doping authorities to nip abuse in the bud, The New York Times reports. GlaxoSmithKline--which sponsored the testing lab for the 2012 Olympics--and Roche have both shared proprietary information with the World Anti-Doping Agency, including data on drugs still in development.
Based on the big promise of GlaxoSmithKline's dolutegravir, the FDA has granted the potential HIV drug a priority review of 6 months rather than the standard 10 months.
Drugmakers might keep the lights on with approvals of new drugs that offer marginal benefits, but pharma chiefs understand that only pioneering therapies pave the way to explosive growth. And GlaxoSmithKline's chairman of R&D has been touting the innovative and advanced nature of contenders in the drug giant's late-stage pipeline.
For years now, evidence has been mounting that a GlaxoSmithKline flu vaccine may have caused narcolepsy in nearly 800 Europeans who received the shot. Now the jab's adjuvant--designed to boost the potency of the vaccine--is under the microscope as the potential cause of the spike in cases of the sleeping disorder.
GlaxoSmithKline has joined up with investigators at Vanderbilt University to quick march their preclinical work on a new obesity drug into clinical studies.
CEO Andrew Witty says GlaxoSmithKline ($GSK) will not go the way of Pfizer ($PFE) and sell off its consumer business that produces nutraceuticals. He told The Telegraph, however, that he does believe the unit needs to be better integrated with the company's drug business.
GlaxoSmithKline has long been the Big Pharma standard-bearer for open clinical trial data, and now the drugmaker has thrown its support behind the AllTrials campaign, a U.K. initiative to register and publicize all studies.
Vaccine-makers Merck and GlaxoSmithKline could boost revenue brought in by their HPV vaccines--Gardasil and Cervarix--if more boys received the shot regimen. A Boston University School of Medicine study shows more parents and guardians saw benefits than drawbacks to vaccinating boys.